By Chris Wack

 

Immix Biopharma Inc. on Tuesday released data showing that IMX-110 plus anti-PD-1 produced extended median survival in a genetic pancreatic cancer mouse model, bolstering its planned 2022 clinical trial.

The company said it would collaborate with BeiGene for a 2022 Phase 1b/2a combination clinical trial of IMX-110 + BeiGene anti-PD-1 tislelizumab in advanced solid tumors.

"We believe this upcoming combination clinical trial will allow us to rapidly expand into multiple oncology indications, " ImmixBio Chief Executive Ilya Rachman said.

The U.S. Food and Drug Administration has approved orphan drug designation for IMX-110 for the treatment of soft tissue sarcoma, and approved rare pediatric disease designation to IMX-110 for the treatment of a life-threatening pediatric cancer in children, rhabdomyosarcoma.

As of January, anti-PD-1 tisleizumab has been approved or granted conditional approval in six cancer indications in China, including non-squamous non-small cell lung cancer, squamous NSCLC, classical Hodgkin's lymphoma, Hepatocellular Carcinoma, and urothelial carcinoma.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

January 25, 2022 11:00 ET (16:00 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more BeiGene Charts.
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more BeiGene Charts.